$PGEN moments are building slowly, and stock is finally moving up and up, I feel it should. 7-year exclusivity, better long-term response rate, expanding market, deepening pipeline, and being profitable by end of 2026. Why it is still so cheap?

A life-threatening inherited disease, hereditary angioedema, with striking benefit from one-shot CRISPR genome editing. Phase 3 randomized, double-blind trial results @NEJM today nejm.org/doi/full/10.1056/NE…

$RCKT sold PPRV for $180M. total cash to $322.6M, but stock is trading under cash value. I do not get it.

$PGEN only valued 1.5B for its monopoly of RRP market. It is moving up. Watch closely if it breaks 5 this time and stays. If it does, time to add ...

An 80-year-old Japanese-American woman with advanced Alzheimer’s—bedbound, incontinent, and speaking only in single syllables for years—just shattered our understanding of neurodegeneration. After a single supervised 5-gram dose of psilocybin mushrooms (Enigma strain), she woke up after 19 hours and did the impossible: Regained full speech (forming complete, coherent sentences) Recovered lost memories (recalling long-forgotten life events) Regained mobility & continence (dressing herself and staying dry) Restored eye contact and humor A follow-up 3-gram dose one month later boosted her verbal fluency and agility even further. These gains lasted for weeks. 🧠 This Is Not A Cure. It’s Something More Profound. The case report, published in Frontiers in Neuroscience (May 27, 2026), proves that functions we assumed were irreversibly destroyed by dementia are actually still there—they are simply trapped behind broken neural gates. Psilocybin bypassed the damage. How? Through explosive, rapid neuroplasticity: The 5-HT2A Switch: Psilocybin floods 5-HT2A serotonin receptors, triggering a massive spike in BDNF (Brain-Derived Neurotrophic Factor). Neural Rewiring: BDNF acts like fertilizer for the brain, driving dendritic spine growth, synaptogenesis, and the repair of broken networks. Circuit Restoration: It downregulates chronic neuroinflammation and re-establishes critical communication between the hippocampus and prefrontal cortex. 🛑 The Tragedy of Our Delay: Johns Hopkins is already studying psilocybin for depression in early-stage cognitive decline. But for late-stage, severe patients? It is an absolute shame that we aren't taking these trials more seriously. Modern medicine has exactly zero treatments that restore lost function in advanced dementia. This single case demands immediate action. We don't have time to wait for a 10-year bureaucratic pipeline while millions of minds fade into the fog. ⚡ The Directive for Compassionate Use: President Trump’s executive order accelerating psychedelic research gives us the exact legal framework we need. We must bypass the standard red tape and establish compassionate use protocols immediately for advanced patients. For millions of families watching their loved ones slip away, this case report is a thunderbolt of hope. The brain still holds secrets, and science moves fast when we get out of its way. What if a single guided experience could give you back one last conversation with the person you love? 🔄 Share this if you want real hope for dementia. Access and research must accelerate NOW. #Psilocybin #Alzheimers #Neuroplasticity #BDNF #MedicalBreakthrough #CompassionateUse #Dementia

$CMPS $ATAI $GHRS Psilocybin for Alzheimer. One case, but it sounds real. Isn't wonderful? Those psychedelic drugs will rewrite human history how to treat CNS diseases/disorders. nypost.com/2026/06/04/health…

Alzheimer's patient gets back speech, continence and memory after 5 grams of experimental drug trib.al/y13eanC

$PGEN I expect forward revenue of 2027 will be over 300M. The company will breakeven by end of 2026. Do not you think it would be sold over $3B in a year or so? The approved drug is expandable to HPV caused cancers, which will add significantly more value.

$XBI recovers 3%, after post-ASCO selling-off. an amazing day for my biotech stocks: $NTLA $IOVA $LQDA $ABVX $REPL $SPRB $CMPS biotech is so volatile. So do not panic when a stock drops like rock. It could be an opportunity.

$ABVX I added some today at 90s.

$ABVX 100. It is recovering quick. After reading so many reports/tweets/discussions, I am convinced that this stock will go much higher.

House bill aims to crack down on China #biotech deals biopharmadive.com/news/binsa… by Kristin Jensen $XBI $IBB

“This draft guidance supports the development of a wide range of cell and gene therapy products, including those that use genome editing, and is part of a broader set of complementary FDA actions in this area. For sponsors developing genome editing therapies, it complements the agency's Plausible Mechanism Framework, providing the scientific tools and data-sharing strategies that allow sponsors to efficiently establish the evidentiary foundation this approach requires.”

I am glad to read it: justice.gov/usao-cdca/pr/fou…

$MREO $OTLK I have both tiny bio stocks. $OTLK more than doubled. Next: $MREO may surprise us, too.

$CMPS $ATAI $GHRS added more. They will only keep going up for years. Those psychedelic drugs are still early, and they will play a huge/increasing role in treating a variety of CNS diseases. They are re-writing history of human medicines, too.

$ABVX initiated a long position at 70s. This is an attractive price, I think, even potential black box warning of malignancy.

I’ll just leave this here... Both in the 40’s for YTD… oh wait 🫣 $ABVX $NTLA